TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00768859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel, trastuzumab and carboplatin
Description: paclitaxel; 70 mg/m2 trastuzumab; 2 mg/kg (loading dose 4 mg/kg) carboplatin; AUC = 3
Study: NCT03940677

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brain MRI
Description: 3 Tesla brain MRI for structural and perfusion evaluation, resting state analysis and functional MRI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brain MRI
Description: 3 Tesla brain MRI for structural and perfusion evaluation, resting state analysis and functional MRI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TMS-EEG
Description: Transcranial magnetic stimulation (TMS) coupled with electroencephalogram (EEG) study

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TMS-EEG
Description: Transcranial magnetic stimulation (TMS) coupled with electroencephalogram (EEG) study

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral and cognitive battery
Description: Emotional, attentional and behavioral assessment using predefine scales and measures

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral and cognitive battery
Description: Emotional, attentional and behavioral assessment using predefine scales and measures

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical evaluation and clinical scales
Description: Neurological evaluation, ophthalmologic assessement, Montreal cognitive assessment (MoCA), movement disorder society (MDS)- UPDRS

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical evaluation and clinical scales
Description: Neurological evaluation, ophthalmologic assessement, Montreal cognitive assessment (MoCA), movement disorder society (MDS)- UPDRS
Study: NCT03549260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIB003
Description: LIB003 or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIB003
Description: LIB003 or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIB003
Description: LIB003 or placebo
Study: NCT03400189

Intervention type: DRUG
Group type: OTHER
Intervention: Sulthiame
Description: Single dose (50, 100, 200 mg)
Study: NCT02971189

Intervention type: DEVICE
Group type: OTHER
Intervention: Librata Endometrial Ablation
Description: The treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
Study: NCT00138294

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: live attenuated and inactivated influenza vaccines
Description: Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: live attenuated and inactivated influenza vaccines
Description: Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers
Study: NCT03986541

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry
Description: Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry
Description: Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.
Study: NCT05474209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes
Description: Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes for 12 months
Study: NCT05000437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: 3x/week high intensity interval training for 12 weeks
Study: NCT00530075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gusperimus
Description: SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles
Study: NCT04015687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-881
Description: Supplied as uncoated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-881
Description: Supplied as uncoated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-881
Description: Supplied as uncoated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Supplied as tablets of LAMICTAL® or generic equivalent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Supplied as tablets of LAMICTAL® or generic equivalent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Supplied as tablets of LAMICTAL® or generic equivalent.
Study: NCT01622335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Description: General anesthesia with Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General anesthesia with oxygen
Description: General anesthesia with(Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
Study: NCT02410876

Intervention type: PROCEDURE
Intervention: Bladder biopsy
Description: Small biopsy of the bladder is taken with cold-cup tongs.

Intervention type: PROCEDURE
Intervention: Bladder biopsy
Description: Small biopsy of the bladder is taken with cold-cup tongs.

Intervention type: PROCEDURE
Intervention: Bladder biopsy
Description: Small biopsy of the bladder is taken with cold-cup tongs.

Intervention type: PROCEDURE
Intervention: Bladder biopsy
Description: Small biopsy of the bladder is taken with cold-cup tongs.

Intervention type: PROCEDURE
Intervention: Bladder biopsy
Description: Small biopsy of the bladder is taken with cold-cup tongs.

Intervention type: PROCEDURE
Intervention: Urodynamic study
Description: Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.
Study: NCT00466167

Intervention type: DRUG
Group type: OTHER
Intervention: Pramipexol Immediate Release

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03599193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Lotion, 0.1%
Description: DFD-03 (Tazarotene Lotion, 0.1%) applied Twice Daily for 1 minute and rinsed off

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene Cream, 0.1%
Description: Tazorac® (tazarotene) Cream, 0.1% applied Once Daily and left for approximately 12 hours
Study: NCT03932058

Intervention type: DRUG
Intervention: Chemotherapy
Description: all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.
Study: NCT02421822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitwits office tool and games
Description: Physician-led narration of Fitwits office tool during well child and subsequent visits over one year with distribution of Fitwits games during first visit.
Study: NCT03596567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib single 100 mg dose in normal healthy subjects
Description: A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow -up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib single 100 mg dose in moderate renal impairment subjects
Description: A single dose of 100 mg glasdegib tablet will be administered to subjects with moderate renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib single 100 mg dose in severe renal impairment subjects
Description: A single dose of 100 mg glasdegib tablet will be administered to subjects with severe renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
Study: NCT02684747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Transfusion
Description: Participants will receive autologous transfusion on Day 21

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control - Normal Saline (Placebo)
Description: Participants will receive saline on Day 21
Study: NCT04418297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-G20
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study: NCT03598998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Given IV
Study: NCT01258036

Intervention type: RADIATION
Intervention: HRpQCT
Description: High Resolution peripheral Quantitative Computerized tomography

Intervention type: RADIATION
Intervention: HRpQCT
Description: High Resolution peripheral Quantitative Computerized tomography

Intervention type: BIOLOGICAL
Intervention: Sampling
Description: Urine and blood samples

Intervention type: BIOLOGICAL
Intervention: Sampling
Description: Urine and blood samples

Intervention type: RADIATION
Intervention: Bone absorptiometry
Description: DXA at the lumbar spine, hip, radius and whole body

Intervention type: RADIATION
Intervention: Bone absorptiometry
Description: DXA at the lumbar spine, hip, radius and whole body
Study: NCT02516267

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiplate ADP®
Description: Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained\> 46 AU, when they will be immediately released to CABG
Study: NCT01591850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5093151
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5093151
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5093151
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir
Description: Multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: Multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: Multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Multiple oral doses
Study: NCT04387656

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Data Collection
Description: Undergo collection of medical information and imaging

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete quality of life questionnaires

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete quality of life questionnaires
Study: NCT01960751

Intervention type: OTHER
Group type: OTHER
Intervention: neurocognitive tests battery
Description: The two groups (exposed: 0.05 to 1 Gy; unexposed: less than 0.05 Gy) will receive the same neurocognitive tests battery.
Study: NCT03795298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN FLX Implant
Description: Left atrial appendage closure with the WATCHMAN FLX device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Market-approved OAC
Description: Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
Study: NCT02410876

Intervention type: PROCEDURE
Intervention: Urodynamic study
Description: Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.

Intervention type: PROCEDURE
Intervention: Urodynamic study
Description: Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.

Intervention type: PROCEDURE
Intervention: Urodynamic study
Description: Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.
Study: NCT01208051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT04197960

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Use thermal energy to destroy tumor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical resection
Description: Resect tumors
Study: NCT03184675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional action observation training
Description: the Four Square Step Test (FSST) performance video for enhancing the dynamic balance and the video including participants' daily activities to increase the gait ability such as walking in a corridor, walking around the hospital, walking to the therapy room, coming out of the ward after opening and closing the door of it, coming in and out of toilet, shifting their blue plate. and bringing something from a refrigerator were produced and watched.

Intervention type: OTHER
Group type: OTHER
Intervention: General action observation training
Description: step 1, looking at the front, while walking comfortably; step 2, looking left and right, while walking; step 3, looking up and down, while walking; step 4, looking at the front, left and right, up and down while walking. After 15 minutes of watching the video, the exercise program with a therapist was conducted to increase the gait ability, for 15 minutes.
Study: NCT00582829

Intervention type: OTHER
Intervention: Generic Print Intervention
Description: Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant.

Intervention type: OTHER
Intervention: Tailored Print Intervention
Description: Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.

Intervention type: OTHER
Intervention: Tailored print plus tailored phone intervention
Description: Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
Study: NCT03439514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797 (PF-07265803)
Description: 400 mg twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797 (PF-07265803)
Description: 400 mg twice daily (BID)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BID
Study: NCT03769974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: Two series of 30 seconds training of motor imagery in each manual engine gesture

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation
Description: Two series of 30 seconds training of action observation training in video format in each manual engine gesture

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Two series of 30 seconds of observation and imagination of a landscape during for each manual motor sequence
Study: NCT05080270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tolerogenic Fibroblasts
Description: administrating single dose of 100 million tolerogenic fibroblasts via intravenous infusion
Study: NCT04383015

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise strategies
Description: Strategies for exercise in type 1 diabetes to maintain glucose control

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise strategies
Description: Strategies for exercise in type 1 diabetes to maintain glucose control

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise strategies
Description: Strategies for exercise in type 1 diabetes to maintain glucose control
Study: NCT00326495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 1 (HER1), c-ErbB) in normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006
Description: Is a potent inhibitor of proto-oncogene c-Raf (c-raf), and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro
Study: NCT03279419

Intervention type: DIAGNOSTIC_TEST
Intervention: Thermal imaging
Description: Use of thermal imaging camera to capture images of peripheral vasculature (hands).

Intervention type: DIAGNOSTIC_TEST
Intervention: Thermal imaging
Description: Use of thermal imaging camera to capture images of peripheral vasculature (hands).
Study: NCT04387214

Intervention type: OTHER
Intervention: survey
Description: online survey
Study: NCT01629862

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: CPAP at therapeutic pressure; ResMed S9 device in fixed pressure mode (Sydney, Australia).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham continuous positive airway pressure
Description: CPAP at non-therapeutic pressure; ResMed S9 device using a ResMed sham mask (Sydney, Australia).
Study: NCT03197935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Description: Atezolizumab was administered as per schedule described in respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to atezolizumab was administered as per schedule described in respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel was administered as per schedule described in the arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel was administered as per schedule described in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin was administered as per schedule described in the arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin was administered as per schedule described in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered as per schedule described in the arms.
Study: NCT00676039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celexa
Description: Celexa 40 mg (Lundbeck, Brand Name)
Study: NCT04526587

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples

Intervention type: OTHER
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03197935

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered as per schedule described in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgrastim
Description: Filgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegfilgrastim
Description: Pegfilgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.